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Abstract Background: Preoperative donation of autolo-
gous blood has been widely used to minimize the potential
risk of allogeneic transfusions in total knee arthroplasty. A
previous study from our center revealed that preoperative
autologous donation reduces the allogeneic blood exposure
for anemic patients but has no effect for non-anemic pa-
tients. Questions/Purposes: The current study investigates
the impact of a targeted blood donation protocol on overall
transfusion rates and the incidence of allogeneic blood trans-
fusions. Methods: Prospectively, 372 patients undergoing
425 unilateral primary knee replacements were preoperative-
ly screened by the Blood Preservation Center between 2009
and 2012. Anemic patients with a hemoglobin level less than
13.5 g/dL were advised to donate blood, while non-anemic
patients did not donate. Results: Non-anemic patients who
did not donate blood required allogeneic blood transfusions
in 5.9% of the patients. The overall rate of allogeneic trans-
fusion was significantly lower for anemic patients who
donated autologous blood (group A, 9%) than those who
did not donate (group B, 33%; p<0.001). Donating autolo-
gous blood did increase the overall transfusion rate of ane-
mic patients to 0.84 per patient in group A compared to 0.41
per patient in group B (p<0.001). Conclusion: This investi-
gation confirms that abandoning preoperative autologous
blood donation for non-anemic patients does not increase
allogeneic blood transfusion rates but significantly lowers
overall transfusion rates.
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Introduction
Total knee arthroplasty (TKA) is one of the most common
orthopedic procedures [14]. Improvements in the surgical tech-
nique over the last four decades have significantly decreased
blood loss and transfusion requirements [21]. However, pa-
tients undergoing TKA are still at risk for allogeneic blood
transfusions. Inherent risks of such transfusions persist despite
improvement in safety and management of allogeneic blood
and range from transfusion reactions and immunomodulation
to the less common but more serious risk of contamination and
viral disease transmission [8, 22]. In addition, allogeneic blood
has been associated with increased incidence of surgical site
infections [2, 18] as well as longer hospital stay [23]. The
preoperative hemoglobin (Hb) level is the most important
factor determining transfusion risk [10, 13].
One of the safest methods to minimize exposure to alloge-
neic blood transfusions is preoperative autologous blood do-
nation (PABD) [12] which is currently considered the standard
of care in TKA [17].
However, autologous blood donation is associated with
increased overall transfusion rates (autologous and alloge-
neic) [6, 9, 12] and wastage rates up to 50% and its efficacy
has been questioned in the more recent literature [2, 16]. A
previous study revealed that the reduction in allogeneic
transfusions associated with PABD was confined to patients
with baseline hemoglobin less than 12.5 g/dL. Non-anemic
patients rarely required transfusions, leading to higher costs
and numbers of units wasted [5]. Based on these data,
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targeted autologous blood donation based on preoperative
hemoglobin was introduced at the authors’ institution.
The current study investigates (1) the impact of targeted
blood donation on overall transfusion rates, (2) the incidence
of allogeneic blood transfusion in non-anemic patients when
preoperative donation is abandoned, and (3) the efficacy of
autologous blood donation in reducing the need for alloge-
neic blood in anemic patients.
Methods
Patients who underwent unilateral knee arthroplasty be-
tween 2009 and 2012 were preoperatively screened by the
Blood Preservation Center as part of a prospective cohort
study. Enrollment into the Blood Preservation Center was
done through the individual private offices of four surgeons
at the authors’ institution. Patients were divided by preoper-
ative hemoglobin level, utilizing 13.5 g/dL as a cutoff.
Patients with a hemoglobin level above 13.5 g/dL were
considered non-anemic and were not asked to donate blood
prior to surgery. Anemic patients with a preoperative hemo-
globin level less than 13.5 g/dL were advised to donate 1 unit
of autologous blood. Gender, age, BMI, preoperative Hb,
date of preoperative Hb measurement, date of autologous
blood donation, number of autologous transfusions, number
of allogeneic transfusions, time of transfusion, postoperative
Hb levels until date of discharge, and in-house complica-
tions were recorded. Patients with bleeding disorders or
other blood management interventions were excluded and
patients whose actual blood management deviated from the
standard protocol were analyzed as separate groups. The
study was approved by the Institutional Review Board at
the authors’ institution.
Three hundred seventy-two patients underwent 425 pri-
mary total knee arthroplasty procedures during the study
period. All procedures were performed under a tourniquet
utilizing a standardized medial parapatellar approach with
hypotensive spinal–epidural anesthesia. Seven non-anemic
patients chose to predonate autologous blood and were
excluded from the analysis and 135 anemic patients did
not donate autologous blood and were analyzed as a separate
group. Among the remaining 418 surgeries, 140 procedures
were performed on males and 278 on females, with a mean
age of 67 years at the time of the surgery (range, 33–
90 years) and BMI of 27 kg/m2 (range, 13–43 kg/m2)
(Table 1).
Of 233 (55%) TKA procedures performed in anemic pa-
tients, 98 donated 1 unit of autologous blood according to
protocol (group A), while 135 did not donate any blood (group
B). Out of 192 procedures performed on non-anemic patients,
185 followed protocol by not donating (group C). Autologous
donation was done on average 10 days prior to the surgery and
patients were given daily oral iron supplementation until the
day of the surgery. Patients received allogeneic transfusions if
their hemoglobin level dropped below 8.0 g/dL and they
displayed clinical symptoms of anemia (tachycardia and/or
hypotension) despite an intravenous fluid bolus. The decision
to transfuse autologous blood was made at the discretion of the
anesthesiologist and medical attending and not according to a
set threshold. All groups were similar in terms of age and BMI
(Table 1 and Fig. 1).
Compared to the prior study, the cut off was moved from
12.5 to 13.5 g/dL to reduce overall exposure to allogeneic
blood. No patient with a hemoglobin level less than 10 g/dL
donated, and such patients usually have their procedures
postponed until the anemia is investigated and treated. Data
were analyzed using a standard two-tailed t test (Microsoft
Excel, Microsoft Corporation, Redmond, WA, USA,
Microsoft Office Professional Plus 2010 Version 14.0.6 for
Windows 7). A p value of less than 0.05 was considered
statistically significant. No patients elected to drop out of the
study at any time (Table 1).
Results
Over the study period, 283 unilateral primary TKAs (67%)
were performed according to the protocol, 98 anemic pa-
tients who donated and 185 non-anemic patients who did
not. Seventy-one percent of patients in the anemic group
who donated blood (group A) received autologous trans-
fusions (Table 2). The overall rate of allogeneic transfusion
was significantly lower for anemic patients who donated
autologous blood (group A, 9%) than those who did not
(group B, 33%; p<0.001). The overall transfusion rate in
group Awas higher (0.84 per patient) than in group B (0.41
per patient; p<0.001).
In the non-anemic group, the overall allogeneic transfusion
rate was 5.9%. Ninety percent of all allogeneic transfusions
were given within 48h of the surgery. No transfusion reactions
were documented in any of the patients. No significant differ-
ences were detected in terms of length of stay or number of
complications between the patient groups. No patient was
Table 1 Demographics of patients screened by the Blood Preservation Center
Anemic Non-anemic Total
PABD No PABD PABD No PABD
Total number 98 135 7 185 425
Male/female 16/82 19/116 3/4 105/80 143/282
Mean age in years (range) 67.0 (33–90) 67.6 (45–90) 68.0 (55–83) 65.8 (34–88) 66.7 (33–90)
Mean BMI in kg m−2 (range) 26.3 (14.7–43.4) 25.8 (12.8–47.7) 33.6 (19.0–73.6) 27.7 (16.1–45.6) 26.9 (12.8–73.6)
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readmitted for anemia, infection, or any thromboembolic
events within a month of discharge (Table 2).
Discharge hemoglobin levels among anemic patients in the
PABD group (group A) were 9.6 g/dL (range, 8 to 11 g/dL), an
average 2.4 g/dL drop from preoperative levels. Similarly,
patients in group B were discharged with a mean Hb of
9.5 g/dL, an average 2.9 g/dL drop from the preoperative
values (p<0.001). Non-anemic patients on the other hand
exhibited a mean 4.1 g/dL drop in Hb to 10.6 g/dL (range,
8.6 to 14.1 g/dL; p<0.001) at the time of discharge.
Discussion
Although autologous blood shares some of the same risks as
allogeneic blood transfusions, including fluid overload and
clerical errors, it significantly decreases the risk of poten-
tially serious adverse effects like viral disease transmission.
In light of the high wastage rates, cost, and the significant
increase of overall transfusion rates, the routine use of
PABD has been questioned. The current study demonstrates
the efficacy of a targeted preoperative autologous blood
donation on preoperative hemoglobin levels.
The current study has a number of limitations. Patients
who were excluded from the study might present a possible
source of selection bias, namely the large number of anemic
patients who did not donate autologous blood. Strict transfu-
sion guidelines were only enforced for allogeneic blood trans-
fusions, and autologous blood was transfused at the discretion
of the covering anesthesiologist. Moreover, although the same
surgical technique was used, the fact that multiple surgeons
contributed to the patient series remains a possible source of
bias. The procedures were performed under spinal epidural
anesthesia which may limit the applicability of our results to
centers utilizing general anesthesia and might increase overall
transfusion requirements because of hypotensive hemodilution.
Preoperative autologous blood donation has an established
role in decreasing allogeneic transfusion requirements [1, 17].
A Cochrane review showed a 68% reduction in exposure to
allogeneic blood with the use of PABD at the expense of a
24% higher overall transfusion rate (allogeneic and/or autolo-
gous) [12]. The Orthopedic Surgery Transfusion Hemoglobin
European Overview study investigated over 4,000 joint
arthroplasty patients and also reported higher overall transfu-
sion rates in patients donating autologous blood [19].
The correlation between preoperative hemoglobin levels
and transfusion risk in joint arthroplasty is well established
in the literature [7, 11, 13, 20]. Patients with hemoglobin
above 13 g/dL have a transfusion risk five times lower than
those with preoperative hemoglobin levels of 11 to 13 g/dL.
Non-anemic patients also have the highest percentage of
wasted autologous blood [15]. Keating et al. showed that
routine autologous donation in patients with a hemoglobin
greater than 13 g/dL resulted in 66% of the autologous blood
being wasted [13]. The benefit of PABD for non-anemic
patients undergoing primary unilateral total joint replace-
ment has been questioned in the literature [3, 4].
A previous study compared overall transfusion rates
between patients who donated autologous blood and a con-
trol group. Autologous blood donation was associated with a
significantly higher total number of transfusions (0.93 per
patient) than control (0.33 per patient, p<0.001), as well as a
lower allogeneic transfusion rate (14% vs. 25%, p<0.03)
[5]. While non-anemic patients displayed almost identical
allogeneic transfusion rates regardless of predonation status
(8% vs. 9%), anemic patients had a higher incidence of
allogeneic transfusions if they did not donate autologous
blood (29% vs. 72%, p=0.006). The current data indicate
that targeting anemic patients for preoperative donation of
autologous blood serves to reduce the number of discarded
units and improve cost effectiveness. Patients who were
enrolled in the targeted donation protocol groups (A + C)
received an average 0.34 units per patient, significantly less
than the average 0.93 observed in the previous study when
PABD was utilized in all patients. Implementation of target
blood management in the private practice environment is
possible. However, enrollment in this protocol is largely
dependent on the surgeon’s dedication to enroll patients.
Ideally, preoperative patient screening and autologous blood
Fig. 1. Patient distribution by number of total knee arthroplasty pro-
cedures according to targeted PABD protocol.
Table 2 Transfusion rates for patients who underwent primary total knee arthroplasty














Group A (n=98) 70 (71%) 9 (9%) 12 0.12 0.84 29
Group B (n=135) 0 44 (33%) 55 0.41 0.41
Group C (n=185) 0 11 (5.9%) 13 0.07 0.07
Patients treated according to
TPABD protocol (n=283)
70 (25%) 20 (7%) 25 0.08 0.34 29
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donation are handled independently of the surgeon’s office
to improve enrollment and should be handled by the hospital
as part of the routine preoperative medical examination.
This investigation confirms that abandoning PABD for
non-anemic patients does not increase allogeneic transfusion
risk and significantly decreases the percentage of wasted au-
tologous blood and therefore reduces overall cost. As such, the
current study supports the use of targeted autologous blood
donation in patients undergoing primary TKA.
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